Isolagen Completes Pivotal Efficacy Portion Of Phase III Studies Of Isolagen Therapy(TM) For Wrinkles
Jul 4th 2008Drug InformationDermatology
Isolagen(TM), Inc. (Amex: ILE) announced the completion of the pivotal efficacy portion of its Phase III clinical studies (IT-R-005/006) investigating the Isolagen Therapy(TM) for the treatment of nasolabial folds, or wrinkles. The last person in each study has completed the primary efficacy follow-up visit, and collation of this data has begun. The Company anticipates that top-line efficacy and safety data analyses from the studies will be reported in August 2008.
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.
